Technology transfer of API from lab to plant is a very critical process for successful API delivery to the client. Diligent planning and execution are required right from selecting plant and equipment, obtaining manufacturing slots, reviewing product development and ensuring the right documentation is delivered on time. At Aurigene, we have a cross-functional team of analysts, chemists, engineers and quality specialists who lead the process of technology transfer. We have extensive experience of scaling up 500+ projects and 1500+ process steps. Our technology transfer procedure from the laboratory to the respective manufacturing facility includes:
Process safety clearance & confirmation of equipment train Analytical method transfers for raw materials, intermediates, in-process tests, and final compound Sharing of process understanding, preparation, and approval of Batch Production Records (BPR)
The following are the steps followed in technology transfer:
Process Safety Clearance and Confirmation of Equipment Train
At Aurigene, we believe in a safe and sustainable manufacturing approach. Controlling chemical reactions and associated hazards is an important aspect of chemical manufacturing. Almost 30% of incidents are caused by chemistry issues due to inadequate study during the developmental phase. Hence, we strive to mitigate hazards and associated risk in scale up by practicing process safety to a great extent.
At Aurigene, there is a very structured methodology for performing process safety. The process includes:
- Literature data and calculations
- Basic screening tests
- Isothermal calorimetry to find out heat of reaction for process
- Adiabatic calorimetry to examine the runaway potential of reactions and compounds and specific measurements like vent sizing calculations
- Generating Hazard Evaluation Report (HER) for scale up assurance
- Based on the safety evaluation, appropriate engineering controls will be adopted prior to batch processing and they will be captured in the Process Hazards Analysis (PHA) and Process Safety Information (PSI) report.
- Pre-Startup Safety Review (PSSR) will be carried out prior to the start of the batch as a checklist on safety to ensure whether all the safety recommendations are being implemented in the specific manufacturing unit or not. Only after that, batch start-up clearance is given on the specific equipment train.
Analytical Method Transfer for Raw Materials, Intermediates, In-process Tests and Final Compound
We have internal Standard Operating Procedures (SOP) which govern the analytical method transfer process. Transfers shall be initiated with pre-approved protocols, followed by batch analysis. SOP guides will fix the acceptance criteria for individual tests to conclude the completion of analytical method transfer.
Decision on Slots at The Plant
After completion of process optimization, we propose the technology transfer date in consultation with the technology transfer team and technology absorption team.
Stage Gate Meetings
PR and D, AR and D, and Process Engineering shall submit the development reports to QA three working days before the proposed technology transfer date. QA shall conduct a gate meeting at least two days before the technology transfer date to review the product development of API using a gate checklist (based on the scope of the project, regulatory submissions/GMP requirements etc.) Timelines shall be provided for the pending action items in the gate checklist. Head QA or designee shall decide on the clearance for the technology transfer depending on the pending action items.
Technology Transfer
Technology transfer shall be conducted based on an optimization study or familiarization report. QA shall hand over all documents along with the technology transfer checklist to the concerned plant QA.
The data generated (document transfer) at the development center will be transferred to the manufacturing facility which would include:
- Raw material list along with specifications and method of analysis
- Optimization report or finalized process for the manufacturing
- Holding study data of reaction mass, wet or dry intermediates
- Recovery or reuse of solvent (as applicable)
- Reprocessing or rework procedures (as applicable)
- Details of analytical methods for in-process controls, intermediates and final compound
- Reference standards
- Process flow diagram
- Equipment justification reports
- Details of process safety evaluation and the recommendations
Based on the technology transfer document batch production record to be generated prior to manufacturing start up
Approval of BPR and Start of Manufacture
After completion of the technology transfer, the required Batch Production Records (BPR) will be generated based on the details provided by the technical team and further will be reviewed and approved by the Quality Assurance (QA) team. Post-completion of the BPR approvals, manufacturing will follow.
We will share the BPR (before it is reviewed and approved by the internal QA team) with the customer team for information purposes only. However, if there are any specific comments from the customer, the BPRs will be further refined as required.
Why Aurigene Pharmaceutical Services?
Experience in scale up of 500+ projects or 1500+ stages
Availability of fast accessible non-GMP pilot plant for risk mitigation
Multifunctional technology transfer and absorption core team
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Resources
JUNE 30, 2022
Advantages of PROTACs over traditional drugs
Proteolysis Targeting Chimera (PROTAC) can overcome most of the limitations of small molecule inhibitors, and they offer several advantages of the traditional concepts of drug discovery by targeted protein degradation. Their Mode of Action (MoA) suggests that a small molecule just needs a brief interaction with its target protein, leading to the loss of function ...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Gastro Retentive Dosage Form
Introduction: An orally-available anti-diabetic candidate that simultaneously targets all three key organs of diabetes: Pancreas, Liver and Muscles. This drug targets the two main defects seen in patients with type 2 diabetes: The pancreas by increasing insulin secretion, in a glucose-dependent manner; and the muscles and liver by decreasing the excess production...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market